Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION

Chest（2023）

引用 0|浏览9

暂无评分

摘要

Introduction Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL 4/13. The efficacy and safety of add-on DPL versus placebo (PBO) in children with asthma have been demonstrated up to 52 weeks (wks) in the VOYAGE study.

查看译文

关键词

liberty asthma,dupilumab,efficacy,long-term

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要